🇺🇸 FDA
Patent

US 11786554

Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene

granted A61KA61K2239/48A61K35/76

Quick answer

US patent 11786554 (Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene) held by Precision BioSciences, Inc. expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Precision BioSciences, Inc.
Grant date
Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K2239/48, A61K35/76, A61K40/11, A61K40/31